Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Product sales, net	$ 10,304,711	$ 5,437,236
Cost of products sold	3,992,811	1,815,924
Gross profit	6,311,900	3,621,312
Selling, general and administrative expenses	12,738,362	10,670,631
Research and development expenses	878,210	307,850
Depreciation and amortization expense	73,836	95,949
Total operating expenses	13,690,408	11,074,430
Loss from operations	(7,378,508)	(7,453,118)
Interest expense, net	(16,360)	(18,081)
Gain on debt extinguishment-PPP	276,180	0
Loss before provision for income taxes and net of equity investments	(7,118,688)	(7,471,199)
Provision for income taxes	(333)	(15,500)
Loss before equity investment	(7,119,021)	(7,486,699)
Deferred profit and divesture-equity investment (See Note F)	242,589	97,887
Net loss	(6,876,432)	(7,388,812)
Net loss attributable to noncontrolling interests	58,115	51,539
Net loss attributable to Milestone Scientific Inc.	$ (6,818,317)	$ (7,337,273)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.10)	$ (0.12)
Diluted (in dollars per share)	$ (0.10)	$ (0.12)
Weighted average shares outstanding and to be issued—
Basic (in shares)	68,829,860	63,061,358
Diluted (in shares)	68,829,860	63,061,358